AI Terminal
Xbrane Biopharma
Board/Management Information • Feb 21, 2020
3128_iss_2020-02-21_898c6690-9f91-462e-b78b-2bf4d7739bb7.pdf
Board/Management Information
Open in ViewerOpens in native device viewer
Maris Hartmanis declines re-election for 2020
Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") has today been informed by the Nomination Committee that Maris Hartmanis has declined re-election at the Annual General Meeting (AGM) 2020. The Nomination Committee will propose a replacing board member and this will be published in connection with the notice to the AGM.
Anders Tullgren, Xbrane's Chairman of the Board, comments: "I would like to take this opportunity to thank Maris for his work on the Board since 2015. His involvement and expertise have been crucial in Xbrane's journey from being a private company to the listing at Nasdaq Stockholm."
Contacts
Martin Åmark, CEO M: +46 (0) 763-093 777 E: [email protected]
Susanna Helgesen, CFO M: +46 (0) 708-278 636 E: [email protected]
About Us
Xbrane is a commercial phase Swedish biopharmaceutical company that develop and produces biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq Stockholm since September 2019 with the ticker XBRANE. For more information please visit www.xbrane.com.
This information is information that Xbrane Biopharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2020-02-21 16:15 CET.